Author

Aykut Üren

Georgetown UniversityORCID 0000-0002-2033-1216Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Approach:mechanistic / dynamical model· 1 Assay:proteomics· 1

Frequent Co-Authors

Andrew Hoy· 1 shared Anqi Feng· 1 shared Arun KrishnarajiD· 1 shared Douglas KungiD· 1 shared Ezgi BağırsakçıiD· 1 shared Katelyn R. AlleyiD· 1 shared Neşe AtabeyiD· 1 shared Okan Sezgin· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMolecular Biology

Andrew Hoy

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Molecular BiologybioRxivPreprintSep 16, 2026

Transcriptome-wide mapping reveals a non-canonical RNA-dependent mechanism of platinum cancer drugs

Arun Krishnaraj, Xinrui Wei, Richi Thakral…·Sreejith J. Nair

The paper identifies cisplatin as an RNA binder and shows its cytotoxicity is partially mediated through RNA binding, revealing a noncanonical mechanism of action.

1 citation

humanbulk RNA-seq

Cancer BiologybioRxivPreprintMay 5, 2026

First-in-Class Small Molecules Inhibit c-MET Activity Through Self-Regulatory Elements in Its Extracellular Domain

Okan Sezgin, Yeliz Yılmaz, Ezgi Bağırsakçı…·Serdar Durdağı

This study identifies small molecules that inhibit c-MET activity by targeting its extracellular domain, showing reduced cell viability and autophosphorylation in HCC cells.

DOI 10.64898/2026.05.01.722033

humanproteomics